Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)

By Pharmaceutical Processing | December 8, 2009

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has enteredinto settlement and license agreements with Wyeth, now part of Pfizer,relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules,37.5 mg, 75 mg and 150 mg, the generic version of Wyeth’s Effexor XR@Capsules, a treatment for major depressive disorder. Pursuant to the license agreement, Mylan will be granted a non-exclusivelicense to the relevant patents that would permit Mylan to launch VenlafaxineHCl ER Capsules in the U.S. on or after June 1, 2011, or earlier in limitedcircumstances. Additional details of the agreement remain confidential.Venlafaxine HCl ER Capsules had U.S. sales of approximately $2.9 billionfor the same strengths for the 12 months ending Sept. 30, according to IMSHealth. Currently, Mylan has 129 abbreviated new drug applications (ANDAs)pending U.S. Food and Drug Administration approval representing $85 billion inannual brand sales, according to IMS. Thirty-seven of these pending ANDAs arepotential first-to-file opportunities, representing $19.2 billion in annualbrand sales, according to IMS.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE